These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34292496)

  • 21. Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis.
    Zhao Z; Wu Y; Geng X; Yuan C; Fu Y; Yang G
    Medicine (Baltimore); 2024 Aug; 103(32):e39213. PubMed ID: 39121324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.
    Rubio-Terrés C; Aguado JM; Almirante B; Cobo J; Grau S; Salavert M; González Antona Sánchez E; López Gutiérrez C; Rubio-Rodríguez D
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1105-1111. PubMed ID: 30989419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective, observational study of fidaxomicin use for
    Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
    J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for
    Dubberke ER; Puckett JT; Obi EN; Kamal-Bahl S; Desai K; Stuart B; Doshi JA
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac435. PubMed ID: 36267250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life experience with fidaxomicin in Clostridioides difficile infection: a multicentre cohort study on 244 episodes.
    Escudero-Sánchez R; Valencia-Alijo A; Cuéllar Tovar S; Merino-de Lucas E; García Fernández S; Gutiérrez-Rojas Á; Ramos-Martínez A; Salavert Lletí M; Castro Hernández I; Giner L; Cobo J
    Infection; 2021 Jun; 49(3):475-482. PubMed ID: 33417171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
    van Prehn J; Reigadas E; Vogelzang EH; Bouza E; Hristea A; Guery B; Krutova M; Norén T; Allerberger F; Coia JE; Goorhuis A; van Rossen TM; Ooijevaar RE; Burns K; Scharvik Olesen BR; Tschudin-Sutter S; Wilcox MH; Vehreschild MJGT; Fitzpatrick F; Kuijper EJ;
    Clin Microbiol Infect; 2021 Dec; 27 Suppl 2():S1-S21. PubMed ID: 34678515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System.
    McDaniel LF; White MN; Obi EN; Kohinke RM; Lockhart ERS; Chipriano DJ; Chen Y; Everson NA
    Infect Dis Ther; 2023 Jan; 12(1):95-107. PubMed ID: 35854204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent
    Abdali ZI; Roberts TE; Barton P; Hawkey PM
    EClinicalMedicine; 2020 Jul; 24():100420. PubMed ID: 32637898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland.
    van Engen A; Casamayor M; Loftus F; Coen M; Garnham A; Watt M; Lacey L
    J Health Econ Outcomes Res; 2015; 2(2):192-206. PubMed ID: 37663580
    [No Abstract]   [Full Text] [Related]  

  • 31. Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.
    Al Momani LA; Abughanimeh O; Boonpheng B; Gabriel JG; Young M
    Cureus; 2018 Jun; 10(6):e2778. PubMed ID: 30112254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada.
    Wagner M; Lavoie L; Goetghebeur M
    Can J Infect Dis Med Microbiol; 2014 Mar; 25(2):87-94. PubMed ID: 24855476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin.
    Sambol SP; Skinner AM; Serna-Perez F; Owen B; Gerding DN; Johnson S
    Microbiol Spectr; 2023 Mar; 11(2):e0051723. PubMed ID: 36975811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
    Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fidaxomicin to prevent recurrent
    Patel D; Senecal J; Spellberg B; Morris AM; Saxinger L; Footer BW; McDonald EG; Lee TC
    JAC Antimicrob Resist; 2023 Feb; 5(1):dlac138. PubMed ID: 36632358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting.
    Lam SW; Neuner EA; Fraser TG; Delgado D; Chalfin DB
    Infect Control Hosp Epidemiol; 2018 Aug; 39(8):924-930. PubMed ID: 29961435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of
    Alsoubani M; Chow JK; Rodday AM; Kent D; Snydman DR
    Open Forum Infect Dis; 2024 Jan; 11(1):ofad622. PubMed ID: 38204563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate
    Ford DC; Schroeder MC; Ince D; Ernst EJ
    Am J Health Syst Pharm; 2018 Aug; 75(15):1110-1121. PubMed ID: 29903711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fidaxomicin for the treatment of
    Skinner AM; Scardina T; Kociolek LK
    Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.